LY3113593
/ Eli Lilly
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
January 27, 2019
Targeting the hepcidin-ferroportin pathway in anemia of chronic kidney disease.
(PubMed, Br J Clin Pharmacol)
- "LY2928057 and LY3113593 pharmacological effects (serum iron and ferritin) were translated from preclinical-to-clinical development. Such interventions may lead to new CKD anemia treatments."
Journal
March 21, 2019
A Study of LY3113593 in Participants With Chronic Kidney Disease
(clinicaltrials.gov)
- P1; N=7; Completed; Sponsor: Eli Lilly and Company; N=80 ➔ 7
Clinical • Enrollment change
1 to 2
Of
2
Go to page
1